Latest Commercial Revenue News

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Tlou Energy has crossed a significant threshold by generating initial revenue from its Lesedi coal bed methane gas through the newly operational Kala Data Centre in Botswana. The milestone validates its integrated gas-to-power model while funding constraints and technical challenges remain key hurdles.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Paradigm Biopharmaceuticals reports a sharp rise in half-year losses as it intensifies investment in its pivotal Phase 3 trial for knee osteoarthritis, setting sights on a critical interim analysis in mid-2026. The company also expands its osteoarthritis pipeline and maintains strong funding amid a strengthening biotech sector.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Winton Land Limited reports a sharp 60% revenue decline in its interim results for H1 FY26 but narrows its net loss and progresses key development projects amid a cautious economic backdrop.

Tlou Energy has commissioned its Kala Data Centre in Botswana, marking the first commercial revenue from its Coal Bed Methane gas resources and validating its integrated gas-to-power strategy.

Temple & Webster has reported a robust 20% increase in half-year revenue to $376 million, expanding its market share and launching successfully into New Zealand. EBITDA remains within guidance despite new market investments.

Brisbane Broncos Limited projects a significant profit increase for 2025, driven by premiership wins in both their NRL and NRLW teams and boosted commercial revenues.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

IODM Limited has secured a significant commercial agreement with Convera to provide its Connect platform to a major UK university, expected to add $600,000 annually from April 2026.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.